Tin tức & Cập nhật

Maintenance niraparib a boon in advanced ovarian cancer
Maintenance niraparib a boon in advanced ovarian cancer
24 Jun 2022 bởiJairia Dela Cruz

Use of niraparib in the maintenance setting appears to minimize the risk of progression in advanced ovarian cancer patients, with surgical timing having little to no effect on the drug’s efficacy, as shown in a post hoc analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 study.

Maintenance niraparib a boon in advanced ovarian cancer
24 Jun 2022
Baricitinib delays, lowers frequency of flares in JIA
Baricitinib delays, lowers frequency of flares in JIA
23 Jun 2022 bởiRoshini Claire Anthony

In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.

Baricitinib delays, lowers frequency of flares in JIA
23 Jun 2022
Upadacitinib for atopic dermatitis may trigger mild, moderate acne
Upadacitinib for atopic dermatitis may trigger mild, moderate acne
23 Jun 2022

Upadacitinib treatment for atopic dermatitis (AD) may cause acne as a side effect, though this is usually only mild or moderate in severity and can be managed by topical intervention, reports a recent study.

Upadacitinib for atopic dermatitis may trigger mild, moderate acne
23 Jun 2022